Amyloid-Fibrinogen Aggregates (“Microclots”) Predict Risks of Disseminated Intravascular Coagulation and Mortality.

Publication date: Mar 20, 2024

Microclots have been associated with various conditions, including post-acute sequelae of SARS-CoV-2 infection. They have been postulated to be amyloid-fibrin(ogen) aggregates, but their role as a prognostic biomarker remains unclear. To examine for their possible clinical utility, blood samples were collected for the first 96 hours from critically ill patients (n=104) admitted to the intensive care unit (ICU). Detection was by staining platelet-poor plasma samples with Thioflavin T and visualized by fluorescent microscopy. Image J software was trained to identify and quantify microclots, which were detected in 44 [42. 3%] patients on ICU admission but not in the remaining 60 [57. 7%] or in 20 healthy controls [0. 0%]. Microclots on admission to ICU were associated with a primary diagnosis of sepsis (microclots present in sepsis=23/44 [52. 3%] vs microclots absent in sepsis=19/60 [31. 7%], P=0. 044). Multicolour immunofluorescence demonstrated that microclots consisted of amyloid-fibrinogen aggregates, which was supported by proteomic analysis. Patients with either a high number or larger-sized microclots had a higher likelihood of developing disseminated intravascular coagulation (DIC) (OR=51. 4 [95% CI=6. 3-6721. 1], P

Concepts Keywords
Amyloid Admission
Blood Aggregates
Hours Amyloid
Immunofluorescence Blood
Poor Coagulation


Type Source Name
drug DRUGBANK Fibrinogen Human
disease MESH Disseminated Intravascular Coagulation
disease MESH post-acute sequelae of SARS-CoV-2 infection
drug DRUGBANK Estrone sulfate
disease IDO blood
disease MESH critically ill
disease MESH sepsis
drug DRUGBANK Dacarbazine

Original Article

(Visited 1 times, 1 visits today)